Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factor

The History of Nerve Growth Factor: From Molecule to Drug

“…As originally hypothesized by the discoverers of NGF, this pleiotropic molecule holds potential research also beyond the eye. In fact, extensive studies are being carried out on the involvement of NGF in the spinal cord [ 32 ], peripheral nerve injuries [ 33 ], psychiatric disorders [ 34 , 35 ], and pain management of chronic diseases [ 38 , 39 , 40 ]; its therapeutic potential in AD [ 51 ], PD [ 31 ], and wound healing in patients with diabetes [ 55 ]; and its role in oncological diseases such as OG [ 59 ]. The development of pharmaceutical compounds designed to target NGF, or its receptors, could also be valuable through temporal dosing strategies for the treatment of autoimmune diseases such as osteoarthritis and rheumatoid arthritis in which NGF is significantly upregulated in the phasic progression of inflammation [ 107 ] and plays a role in mediating neuropeptides and neurotransmitters to affect innate and adaptive immune responses [ 108 ].…”

“…So far, NGF has attracted significant research attention because of its potential applications in various therapeutic fields: neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis [ 28 , 29 , 30 , 31 ], spinal cord injury [ 32 ], and peripheral nerve injury [ 33 ]; Rett syndrome [ 33 ]; psychiatric disorders including depression, anxiety, and post-traumatic stress disorder [ 34 , 35 ]; and neurodevelopmental disorders such as autism spectrum disorder and attention deficit hyperactivity disorder [ 36 , 37 ]. Targeting the NGF pathway has been suggested in pain management for chronic conditions such as neuropathic pain [ 38 , 39 , 40 ]. The use of NGF as a therapeutic agent has also been considered for neuronal survival, stroke rehabilitation [ 41 ], and the treatment of ocular disorders such as glaucoma and age-related macular degeneration [ 42 , 43 ].…”

Preparation and application of fluorescent monoclonal antibodies recognizing goat CD4+CD25+ regulatory T cells

“…Hybridoma lines producing mAbs that only recognized the recombinant proteins but not the tag protein were screened by ELISA. Positive hybridoma cells that had been cloned three times were used to make ascites (Li et al 2019b ; Liu et al 2022 ; Ma et al 2019 ). The ascites of mice were purified by protein G agarose (Beyotime, Shanghai, China), labeled with a conjugation kit (Bioss, Beijing, China).…”